Atea Pharmaceuticals, Inc. (AVIR)Healthcare | Biotechnology | Boston, United States | NasdaqGS
5.74 USD
+0.04
(0.702%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.74 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:54 p.m. EDT
AVIR is a high-risk, high-reward stock with a low beta, indicating it is less volatile than the market. However, the recent price history shows a range-bound movement with no clear upward or downward trend. The stock has a negative forward P/E and EPS, indicating poor earnings performance, and no dividend history. While there is some positive news and insider buying, the fundamentals are weak, and the forecasting model shows little predictive power. Short-term traders may look for short-term momentum, but long-term investors should be cautious due to the lack of earnings growth and dividend yield. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.231643 |
| AutoETS | 0.231644 |
| AutoTheta | 0.231801 |
| MSTL | 0.235960 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 15.82 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.134 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.306 |
| Market Cap | 457,317,728 |
| Forward P/E | -4.14 |
| Beta | 0.16 |
| Website | https://ateapharma.com |
As of April 11, 2026, 2:54 p.m. EDT: Options speculators are showing mixed signals. The calls show higher open interest and volume on the 7.5 strike, indicating potential bullish sentiment, while puts have higher volatility and open interest on lower strikes, suggesting some bearish positioning. The ATM strikes are heavily traded, which could indicate a focus on the current price range. The overall options activity suggests uncertainty, with a mix of both bullish and bearish bets.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.99300694 |
| Address1 | 225 Franklin Street |
| Address2 | Suite 2100 |
| All Time High | 94.174 |
| All Time Low | 2.455 |
| Ask | 7.19 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 312,050 |
| Average Daily Volume3 Month | 547,381 |
| Average Volume | 547,381 |
| Average Volume10Days | 312,050 |
| Beta | 0.157 |
| Bid | 4.12 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 3.525 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.74 |
| Current Ratio | 7.817 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.805 |
| Day Low | 5.61 |
| Debt To Equity | 0.306 |
| Display Name | Atea Pharmaceuticals |
| Earnings Call Timestamp End | 1,772,746,200 |
| Earnings Call Timestamp Start | 1,772,746,200 |
| Earnings Timestamp | 1,772,744,400 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -178,980,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.873 |
| Enterprise Value | 156,330,752 |
| Eps Current Year | -1.93 |
| Eps Forward | -1.385 |
| Eps Trailing Twelve Months | -1.94 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.2522 |
| Fifty Day Average Change | 0.48779964 |
| Fifty Day Average Change Percent | 0.092875294 |
| Fifty Two Week Change Percent | 99.3007 |
| Fifty Two Week High | 6.45 |
| Fifty Two Week High Change | -0.71000004 |
| Fifty Two Week High Change Percent | -0.11007753 |
| Fifty Two Week Low | 2.455 |
| Fifty Two Week Low Change | 3.2849998 |
| Fifty Two Week Low Change Percent | 1.3380855 |
| Fifty Two Week Range | 2.455 - 6.45 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,604,064,600,000 |
| Float Shares | 59,449,715 |
| Forward Eps | -1.385 |
| Forward P E | -4.1444044 |
| Free Cashflow | -71,376,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -146,534,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13357 |
| Held Percent Institutions | 0.76569 |
| Implied Shares Outstanding | 79,672,083 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. |
| Long Name | Atea Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 457,317,728 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_252824153 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -158,348,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 454,130,873 |
| Number Of Analyst Opinions | 3 |
| Open | 5.78 |
| Operating Cashflow | -132,031,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 284 8891 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.74 |
| Post Market Time | 1,776,456,604 |
| Previous Close | 5.7 |
| Price Eps Current Year | -2.9740932 |
| Price Hint | 2 |
| Price To Book | 1.6283687 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.587 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 0.701754 |
| Regular Market Day High | 5.805 |
| Regular Market Day Low | 5.61 |
| Regular Market Day Range | 5.61 - 5.805 |
| Regular Market Open | 5.78 |
| Regular Market Previous Close | 5.7 |
| Regular Market Price | 5.74 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 418,853 |
| Return On Assets | -0.28754 |
| Return On Equity | -0.44337 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 79,672,083 |
| Shares Percent Shares Out | 0.0952 |
| Shares Short | 7,586,717 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,880,520 |
| Short Name | Atea Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.12189999 |
| Short Ratio | 11.66 |
| Source Interval | 15 |
| State | MA |
| Symbol | AVIR |
| Target High Price | 10.5 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.83333 |
| Target Median Price | 10.0 |
| Total Cash | 301,830,016 |
| Total Cash Per Share | 3.788 |
| Total Debt | 843,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.94 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.82915 |
| Two Hundred Day Average Change | 1.9108498 |
| Two Hundred Day Average Change Percent | 0.49902716 |
| Type Disp | Equity |
| Volume | 418,853 |
| Website | https://ateapharma.com |
| Zip | 2,110 |